The Buy rating maintained by Alliance Global Partners and the significant increase in the price target from $6.5 to $18 indicate a positive outlook for Tonix Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's potential.